^
    Back
    Association details:
    Biomarker:SLFN11 expression
    Cancer:Small Cell Lung Cancer
    Drug:veliparib (ABT-888) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

    Published date:
    08/10/2018
    Excerpt:
    SLFN11 expression was associated with improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of PARP-inhibitor sensitivity in SCLC.
    DOI:
    10.1200/JCO.2018.77.7672
    Trial ID:
    NCT01638546